Annals of Surgical Oncology, Vol 4, Issue 2 141-148, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells

J. F. Buell, E. Reed, K. B. Lee, R. J. Parker, D. J. Venzon, K. Amikura, S. Arnold, D. L. Fraker and H. R. Alexander
Surgical Metabolism Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892. USA.

BACKGROUND: Peritoneal carcinomatosis is a difficult management problem, and intraperitoneal treatment approaches may provide an opportunity to intensify dose and minimize toxicity. The current experiments were conducted to characterize the cytotoxic effects of cisplatin (cDDP), tumor necrosis factor (TNF), and hyperthermia (HT) on a gastric cancer cell line in vitro under conditions achievable with intraperitoneal treatment. METHODS: Seoul National University gastric cancer cell line (SNU-5), a poorly differentiated gastric cancer cell line, was tested for sensitivity to various doses of cDDP, TNF, or combinations of the two at normothermia (37 degrees C) or HT (42.5 degrees C). The effect of TNF on cellular rates of cDDP accumulation, efflux, and cDDP-DNA adduct formation were evaluated using atomic absorbance spectrometry with Zeemen background correction. RESULTS: During a 2-h exposure to various doses of cDDP HT, we observed a supraadditive cytotoxicity of SNU-5 with 1 to 50 micrograms/ml of TNF (p2 = 0.0001). In the presence of the three-agent combination (HT, TNF, and cDDP) we observed statistically significant increases in total cellular accumulation of cisplatin (p2 = 0.016); a nonsignificant decrease in cellular efflux of drug (p2 = 0.098); and a 40% increase in persistent cisplatin DNA damage as measured by atomic absorption spectrophotometry (p2 = 0.06). These patterns were specifically not seen with the combinations of cDDP and HT, or cDDP and TNF. CONCLUSIONS: These data provide the experimental basis for the use of TNF and cDDP with HT in the treatment of gastric cancer and support the investigation of these agents in vivo in the regional treatment of peritoneal carcinomatosis.

This article has been cited by other articles:

				W. Walther, F. Arlt, I. Fichtner, J. Aumann, U. Stein, and P. M. Schlag Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-{alpha} expression Mol. Cancer Ther., January 1, 2007; 6(1): 236 - 243. [Abstract] [Full Text] [PDF]

				C. R. Rossi, S. Mocellin, P. Pilati, M. Foletto, L. Campana, L. Quintieri, G. L. De Salvo, and M. Lise Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor {alpha} and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas Ann. Surg. Oncol., May 1, 2005; 12(5): 398 - 405. [Abstract] [Full Text] [PDF]

				C. R. Rossi, M. Foletto, S. Mocellin, P. Pilati, and M. Lise Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-{alpha} and Melphalan for Bulky In-Transit Melanoma Metastases Ann. Surg. Oncol., February 1, 2004; 11(2): 173 - 177. [Abstract] [Full Text] [PDF]